UBS Remains a Buy on Merck KGaA (0O14)

Tip Ranks
2025.11.13 11:06
portai
I'm PortAI, I can summarize articles.

UBS analyst Matthew Weston has reaffirmed a Buy rating on Merck KGaA, setting a price target of €150.00. Weston, who specializes in the Healthcare sector, has an average return of 7.1% and a 69.77% success rate on his stock recommendations. Additionally, J.P. Morgan's Richard Vosser also issued a Buy rating for Merck KGaA today, while Stifel Nicolaus maintained a Sell rating on the stock.

UBS analyst Matthew Weston maintained a Buy rating on Merck KGaA today and set a price target of €150.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and Roche Holding AG. According to TipRanks, Weston has an average return of 7.1% and a 69.77% success rate on recommended stocks.

In addition to UBS, Merck KGaA also received a Buy from J.P. Morgan’s Richard Vosser in a report issued today. However, on the same day, Stifel Nicolaus maintained a Sell rating on Merck KGaA (LSE: 0O14).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.